Deshpande et al. conclude that ethambutol (EMB) doses of Ն50 mg/kg of body weight twice a week would be the optimal clinical dose for the treatment of Mycobacterium avium (2). This was based on pharmacokinetic-pharmacodynamic studies using a hollow-fiber system model of intracellular M. avium, mimicking ethambutol human-like pharmacokinetics. This adds important information on the relationship between ethambutol exposure, dose schedule, and M. avium response.
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We thank Dr. Alffenaar and Dr. van der Werf for their interest in our paper. The authors are to be commended for keeping the focus on treatment of disseminated Mycobacterium avium infection, a focus unfortunately abandoned by many researchers. We also thank them for highlighting an important concept, which is that of complexity of dosing in obese patients. We agree with many of their suppositions but would also like to challenge one part of their assertions.
The authors' main point in the foregoing letter is that obese patients may be at greater risk of toxicity from ethambutol. We concur, based on the theoretical grounds that they advance. Obesity profoundly alters pharmacokinetics of drugs, sometimes increasing the clearance of drugs as weight increases and sometimes increasing the volume of distribution as weight increases. This would reduce drug concentrations in obesity rather than increase them. However, while ethambutol is metabolized by alcohol dehydrogenase to an aldehyde, 80% of parent drug is excreted unchanged by the kidney, so that the effect of weight on ethambutol clearance either via oxidation or via alteration of renal function is likely to be minimal. On the other hand, their argument of a lower volume of distribution per kg of body weight due to water-fat partition coefficient is valid, so that higher concentrations could be achieved per mg/kg of ethambutol dose. Given that the pharmacokinetics of the drug are likely driven by distribution and redistribution of the drug (in addition to renal function), obesity could lead to a different concentration-time profile shape. This brings us to a central toxicodynamic question: what part of the ethambutol concentration-time curve (time above threshold or area under the concentration-time curve [AUC] or maximum concentration of drug in serum [C max ]) correlates with the ocular toxicity? Indeed, the effect of dosing schedule on toxicity is well known, and intermittent dosing has been used to reduce the toxicity of drugs whose efficacy is concentration driven but for which toxicity is driven by time above threshold (4-7). Based on our analysis of earlier clinical studies by others (1, 2) , we suspect that as long as high ethambutol doses are administered intermittently as opposed to a daily regimen, the high doses would likely be associated with less ocular toxicity. Obviously, this needs prospective evaluation.
Where we differ with them is on the solution. We are concerned about the proposed ethambutol dosing algorithm for obese patients using ideal body weight. Although their study demonstrated ethambutol-based ocular toxicity in 6 patients, only 2 of the 6 had a body mass index (BMI) of Ͼ20 kg/m, and all 6 received daily therapy regimens (3). We are concerned about generalizing from such a small data set. Since the pharmacokinetic parameter associated with ethambutol toxicity is still unknown, as are the population and compartmental pharmacokinetic parameters of ethambutol in obese patients, using their proposed formula to calculate ethambutol doses that would reduce toxicity is still premature. We first need to understand the extent to which the obesity contributes to pharmacokinetic variability of ethambutol and to what extent the obesity contributes to the ethambutol concentration exposure threshold associated with toxicity. With that knowledge more deliberate dose adjustments could then be made. Nevertheless, their concern about potential toxicity during dosing of obese patients is important to note and will be studied further.
